Avalo Therapeutics, Inc.

( )
AVTX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
SAVACassava Sciences, Inc. -1.04%52.310.0%$662.88m
CTLTCatalent, Inc. 0.77%137.142.0%$167.89m
VRXValeant Pharmaceuticals International, Inc. 0.67%28.4014.1%$167.11m
PRGOPerrigo Co. Plc 0.07%42.796.9%$138.90m
ICLRICON plc 1.64%274.392.8%$114.01m
HZNPHorizon Therapeutics Plc 0.18%109.965.5%$107.41m
INDPIndaptus Therapeutics, Inc. 1.81%8.420.0%$95.76m
JAZZJazz Pharmaceuticals Plc 0.35%129.552.1%$94.01m
ARGXargenx SE -1.84%310.550.0%$67.16m
BHCBausch Health Cos., Inc. 0.67%28.400.0%$57.19m
ENDPEndo International Plc 9.06%3.018.5%$51.16m
UTHRUnited Therapeutics Corp. 1.55%201.9214.0%$49.23m
AXSMAxsome Therapeutics, Inc. -1.03%30.891.8%$39.05m
IRWDIronwood Pharmaceuticals, Inc. -0.47%12.619.5%$20.77m
TBPHTheravance Biopharma, Inc. 1.69%7.227.4%$20.63m

Company Profile

Avalo Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.